Literature DB >> 2455840

The selectivity of xamoterol, prenalterol, and salbutamol as assessed by their effects in the presence and absence of ICI 118,551.

P M McCaffrey1, J G Riddell, R G Shanks.   

Abstract

The selectivity of single oral doses of xamoterol, 200 mg, prenalterol, 50 mg, and salbutamol, 8 mg, was compared in eight healthy male volunteers by measuring their effects on sleeping heart rate, supine heart rate, blood pressure, forearm blood flow, finger tremor, and exercise heart rate in the presence and absence of the specific beta 2-adrenoceptor antagonist ICI 118,551, 25 mg. Xamoterol, 200 mg, increased sleeping heart rate and systolic blood pressure, decreased exercise heart rate, and had no effect on diastolic blood pressure, forearm blood flow, or finger tremor. The concurrent administration of ICI 118,551, 25 mg, did not alter these results. Supine heart rate was increased by xamoterol and did not differ from that for xamoterol with ICI 118,551. Prenalterol, 50 mg, increased sleeping heart rate, supine heart rate, systolic blood pressure, forearm blood flow, and finger tremor, decreased diastolic blood pressure, and had no effect on exercise tachycardia. The concurrent administration of ICI 118,551 with prenalterol reduced the increase in sleeping heart rate, supine heart rate, and forearm blood flow, and reduced the fall in diastolic blood pressure caused by prenalterol alone. The increase in finger tremor following prenalterol with ICI 118,551 tended to be less than that following prenalterol. Salbutamol, 8 mg, increased sleeping heart rate, supine heart rate, systolic blood pressure, forearm blood flow, finger tremor, and exercise heart rate, and caused a fall in diastolic blood pressure. When salbutamol, 8 mg, was administered with ICI 118,551, 25 mg, the only changes detected were a small initial increase in finger tremor and a small rise in diastolic blood pressure.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2455840     DOI: 10.1097/00005344-198805000-00006

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  11 in total

1.  Ischaemic left ventricular failure: evidence of sustained benefit after 18 months' treatment with xamoterol.

Authors:  E Vigholt-Sørensen; O Faergeman
Journal:  Br Heart J       Date:  1990-09

Review 2.  Xamoterol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  R Furlong; R N Brogden
Journal:  Drugs       Date:  1988-10       Impact factor: 9.546

3.  Effects of xamoterol on resting and exercise haemodynamics in patients with chronic heart failure.

Authors:  S J Virk; M K Davies
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

4.  Regional differences of beta 1- and beta 2-adrenoceptor-mediated functions in feline heart. A beta 2-adrenoceptor-mediated positive inotropic effect possibly unrelated to cyclic AMP.

Authors:  H Lemoine; A J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-07       Impact factor: 3.000

5.  Evaluation of the effect on heart rate variability of a beta2-adrenoceptor agonist and antagonist using non-linear scatterplot and sequence methods.

Authors:  C G Hanratty; B Silke; J G Riddell
Journal:  Br J Clin Pharmacol       Date:  1999-02       Impact factor: 4.335

6.  Ketotifen and cardiovascular effects of xamoterol following single and chronic dosing in healthy volunteers.

Authors:  R F Schäfers; I Karl; K Mennicke; A E Daul; T Philipp; O E Brodde
Journal:  Br J Clin Pharmacol       Date:  1999-01       Impact factor: 4.335

7.  Selective and full beta 1-adrenoceptor agonist action of a catechol derivative of denopamine (T-0509) in the guinea-pig cardiac muscle and trachea: comparison with denopamine, xamoterol and isoprenaline.

Authors:  H Yabana; H Watanabe; H Narita; T Nagao
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

8.  Evaluation of in vivo partial beta 1/beta 2-agonist activity: a dose-ranging study with carteolol.

Authors:  N M Wheeldon; D G McDevitt; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1992-04       Impact factor: 4.335

9.  Characterization of the beta-adrenoreceptors which mediate the isoprenaline-induced changes in finger tremor and cardiovascular function in man.

Authors:  T H Pringle; J G Riddell; R G Shanks
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

10.  Pharmacodynamic without pharmacokinetic interaction between cicloprolol, a partial beta 1-adrenoceptor agonist, and digoxin in healthy subjects.

Authors:  S Weber; A Kahan; J L Pinquier; J Julien; P Rosenzweig; G Bianchetti; P L Morselli; O Dessault; D De Lauture; G Strauch
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.